| General | ||
| BD | Batten disease | |
| BDFA | Batten Disease Family Association | |
| BDSRA | Batten disease support and research Association | |
| CNS | Clinical Nurse specialist | |
| EMA | European Medicine Agency | |
| EU | European Union | |
| FDA | Federal Drug Administration | |
| LSD | Lysosomal Storage Disease | |
| MHRA | Medicines & Healthcare products Regulatory Agency | |
| NCL | Neuronal Ceroid Lipofuscinoses | |
| NHS | National Health Service | |
| NICE | National Institute for Health and Care excellence | |
| PO | Patient Organisation | |
| HTA | Human Tissue Authority (UK) | |
| Science | ||
| PPT1 | palmitoyl-protein thioesterase 1 | |
| TPP1 | tripeptidyl peptidase 1 | |
| Medical | ||
| CNS | Central nervous system | |
| EHCP | Education, health and care plans | |
| ERT | Enzyme replacement Therapy | |
| GT | Gene Therapy | |
| HST |
|
|
| ICU | Intensive Care Unit | |
| ICV | intro cerebroventricular | |
| INCL | Infantile Batten disease | |
| IVF |
|
|
| JNCL | Juvenile Batten Disease | |
| LINCL | Late Infantile Batten disease | |
| PGD | pre-implantation genetic diagnosis | |
| SEN | Special educational needs | |
| SRT | Substrate Reduction Therapy | |
| VI | Visual Impairment | |
| vLINCL | Variant late infantile Batten disease |
